1 Outcomes for Patients with ST-Elevation Myocardial Infarction in Hospitals With and Without Onsite Coronary Artery Bypass Graft Surgery: The New York.

Slides:



Advertisements
Similar presentations
ACTION Registry (Acute Coronary Treatment and Intervention Outcomes Network) Initial Report 1st Quarter 2007 Results Report prepared by: www. ncdr.com.
Advertisements

ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,
Copyright © 2003 Pearson Education, Inc. Slide 1 Computer Systems Organization & Architecture Chapters 8-12 John D. Carpinelli.
1 Copyright © 2013 Elsevier Inc. All rights reserved. Appendix 01.
Properties Use, share, or modify this drill on mathematic properties. There is too much material for a single class, so you’ll have to select for your.
OPTN Modifications to Heart Allocation Policy Implemented July 12, 2006 Changed the allocation order for medically urgent (Status 1A and 1B) patients Policy.
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26:
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2008 J Heart Lung Transplant 2008;27:
© 2010, American Heart Association. All rights reserved. Hospital Performance Recognition with the Get with the Guidelines Program and Mortality for Acute.
© 2010, American Heart Association. All rights Association of Hospital Primary Angioplasty Volume in ST-Segment Elevation Myocardial Infarction With Quality.
Break Time Remaining 10:00.
Clinique Médicale du Ring
Off pump CABG has been performed for the first time 40 years ago. Although conventional CABG is considered both safe and effective, the use of CBP.
UNIVERSITÄT LEIPZIG H E R Z Z E N T R U M Randomized Comparison of Percutaneous Coronary Intervention with Sirolimus-Eluting Stents versus Coronary Artery.
1 RA III - Regional Training Seminar on CLIMAT&CLIMAT TEMP Reporting Buenos Aires, Argentina, 25 – 27 October 2006 Status of observing programmes in RA.
Basel-ICU-Journal Challenge18/20/ Basel-ICU-Journal Challenge8/20/2014.
1..
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
Asthma in Minnesota Slide Set Asthma Program Minnesota Department of Health January 2013.
Associations Between Outpatient Heart Failure Process of Care Measures and Mortality Gregg C. Fonarow, Nancy M. Albert, Anne B. Curtis, Mihai Gheorghiade,
Pexelizumab for the Reduction of Infarction and Mortality in Coronary Artery Bypass Graft ll (PRIMO-CABG II) Trial Presented at The American College of.
Paclitaxel-eluting Stents vs Brachytherapy for In-stent Restenosis (TAXUS V ISR) Trial Presented at The American College of Cardiology Scientific Session.
Analyzing Genes and Genomes
Essential Cell Biology
Clock will move after 1 minute
PSSA Preparation.
Essential Cell Biology
Murach’s OS/390 and z/OS JCLChapter 16, Slide 1 © 2002, Mike Murach & Associates, Inc.
The Influence of Radial vs. Femoral Access on Acute Blood Loss in Patients Undergoing Percutaneous Coronary Intervention Amit Nanda 1, Eric Novak MS 2,
“Hospital Performance Recognition with the Get with the Guidelines Program and Mortality for Acute Myocardial Infarction and Heart Failure Paul A Heidenreich,
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
Validation of Mayo Clinic Risk Adjustment Model for In-Hospital Mortality following Percutaneous Coronary Interventions using the National Cardiovascular.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts Laura Mauri, MD, MSc; Treacy Silverstein, B.Sc.; Ann Lovett,
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 9: Cardiovascular Disease in Patients With ESRD.
Is Veteran User Status an Independent Risk Factor for Mortality After Private Sector CABG? William B. Weeks, MD, MBA Dorothy A. Bazos, Ph.D. David M. Bott,
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
Can we better protect patients who undergo revascularization? Beneficial effects of short- and long-term trimetazidine MR therapy in patients undergoing.
Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Coronary Artery Disease and its Treatments
2016 Annual Data Report, Vol 1, CKD, Ch 4
Figure 9.1 Causes of death in ESRD patients,
The MASS-DAC Study.
Thirty-day Readmissions Following CABG Surgery in New York JACC: Cardiovascular Interventions 2011;4(5): Hannan EL, Zhong Y, Lahey SJ, Culliford.
Successful CTO PCI Associated with Lower Mortality Risk
Chapter 8: Cardiovascular Disease in Patients with ESRD
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
Shikhar Agarwal, MD, MPH, Aatish Garg, MD, Akhil Parashar, MD, Lars G
New-Onset Postoperative Atrial Fibrillation and Long-Term Survival After Aortic Valve Replacement Surgery  Giovanni Filardo, PhD, MPH, Cody Hamilton,
Global Registry of Acute Coronary Events: GRACE
Appropriateness of Coronary Revascularization for Patients Without Acute Coronary Syndromes Edward L. Hannan, PhD; Kimberly Cozzens, MA; Zaza Samadashvili,
No Financial Disclosure or Conflict of Interest
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.
Maintenance of Long-Term Clinical Benefit with
Atlantic Cardiovascular Patient Outcomes Research Team
Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.
Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.
Figure 9.1.a Causes of death in ESRD patients,
Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.
Presentation transcript:

1 Outcomes for Patients with ST-Elevation Myocardial Infarction in Hospitals With and Without Onsite Coronary Artery Bypass Graft Surgery: The New York State Experience Hannan EL, Zhong Y, Racz M, Jacobs AK, Walford G, Cozzens K, Holmes DR, Jones RH, Hibberd M, Doran D, Whalen D, King SB III. Circulation: Cardiovascular Interventions, published ahead of print 11/10/09.

2 Background The benefit of primary percutaneous coronary interventions (P-PCI) for patients with ST-elevation myocardial infarction (STEMI) has been well- documented. However, controversy still exists as to whether PCI should be expanded to hospitals without coronary artery bypass graft (CABG) surgery. Elective PCI at hospitals without onsite CABG surgery is currently not recommended in the most recent ACC/AHA guidelines

3 Purpose of Study To compare long- and short-term outcomes for STEMI patients in NY hospitals without CABG surgery backup (P-PCI centers) to those in hospitals with backup (called Full Service (FS) centers).

4 Methods Patients and Outcomes: STEMI Patients Undergoing PCI – Observational study of 1735 patients who were discharged after PCI for STEMI between 1/1/03 and 12/31/06 in P-PCI centers were propensity-matched to 8817 patients in full service (FS) centers to obtain 1729 pairs of patients with very similar propensity scores. – These patients were followed through the end of 2006 and outcomes of patients treated in P-PCI centers were compared with outcomes of patients in FS centers.

5 Methods, Cont’d Patients and Outcomes: STEMI Patients Undergoing PCI – Outcomes that were examined included in- hospital mortality and need for CABG surgery, and three-year mortality, repeat target vessel PCI and subsequent revascularization.

6 Methods, Cont’d Patients and Outcomes: STEMI Patients Not Undergoing PCI – Patients: Observational study comparing all STEMI patients presenting at P-PCI centers not undergoing PCI (34.3% of all pts.) and all STEMI patients presenting at FS centers not undergoing PCI (30.3% of all pts.)

7 Methods, Cont’d Patients and Outcomes: STEMI Patients Not Undergoing PCI – Outcome: The outcome used was risk- adjusted in-hospital mortality using the variables used in the CMS AMI reports for the risk-adjustment process (no out-of- hospital mortality was available for these pts).

8 Results Variables used in the propensity matching included: – Age, sex, race – Ejection fraction, congestive heart failure, previous AMI, shock, hemodynamic instability – Several comorbidities (renal failure, COPD, diabetes, carotid/cerebrovascular disease, peripheral vascular disease, ventricular arrhythmia – Previous revascularization – Anatomic group (no. of vessels diseased and presence absence of proximal LAD disease)

9 Results Prior to propensity matching, patients in FS centers were sicker (lower ejection fractions, higher comorbidity rates, more likely to be hemodynamically unstable or in shock, more likely to have congestive heart failure). After propensity matching, there were no differences based on an examination of % standardized differences in risk factor prevalences.

10 Results: Short-Term Outcomes for Pts with PCI For patients undergoing PCI, there were no differences for in-hospital/30-day mortality (2.3% for P-PCI centers vs. 1.9% for FS centers (P=0.40)), emergency CABG surgery immediately following PCI (0.06% vs. 0.35%, P=0.06). However, P-PCI centers had a lower same/next day CABG rate (0.23% vs. 0.69%, P=0.046).

11 Results: Short-Term Outcomes for Pts without PCI A higher percentage of STEMI patients arriving at P-PCI centers did not undergo PCI (34.3% vs. 30.3%) These patients had significantly higher mortality rates (28.5% vs. 22.3%, adjusted OR =1.38, 95% CI (1.10, 1.77)). After removing the patients who died within 2 hours of arriving at the hospital, P-PCI center patients still had higher mortality rates (adjusted OR= 1.39, 95% CI (1.10, 1.77)).

12 Results: Longer-Term Outcomes for Pts with PCI For patients undergoing PCI, there were no differences in three-year mortality (6.8% vs. 6.9%, P=0.63) or subsequent revascularization (23.4% vs. 20.7%, P=0.11). However, P-PCI centers had higher repeat target vessel PCI rates (12.4% vs. 9.2%, P=0.0005).

13 Mortality Rates and P-values for Matched STEMI Patients Undergoing Primary PCI in P-PCI Centers and Full Service Centers: New York, Jan Dec Short-Term OutcomesRate in Primary PCI Centers Rate in Full Service Centers P-value In-Hospital/30 day Mortality2.31%1.91%0.40 Emergency CABG Surgery 0.06%0.35%0.06 Same day/next day CABG 0.23%0.69%0.046 Longer-Term Outcomes Rate in Primary PCI Centers Rate in Full Service Centers P-value 3-Year Mortality 7.1%5.9% Year Repeat Target Vessel PCI 12.1%9.0% Year Subsequent Revascularization 23.8% 21.5% 0.52

14 Caveats Operators in New York P-PCI centers were required to perform at least 200 PCIs in the past 3 years, 75 PCIs per year and 11 P-PCIs per year on a regular basis. Also, P-PCI centers were required to ensure 24/7/365 coverage for P-PCI, maintain a volume of 36 P-PCIs per year, and maintain an active affiliation with a high-volume FS center. Hence, P-PCI center results in less restrictive settings could be worse. The study is observational and therefore subject to possible selection bias. However, propensity matching was used to adjust for baseline differences. Also, it would be impractical to conduct an RCT for this type of study given that many patients are transported by ambulance.

15 Caveats, Cont’d It is possible that P-PCI centers were at a disadvantage because they were in a startup period during which teams were becoming accustomed to one another and to a new procedure being performed in the hospital. To test for this bias, we repeated the analyses after excluding the first year of operation, and found that the results were essentially the same (the significant differences remained).

16 Conclusions Summary: No differences between P-PCI centers and FS centers were found in in-hospital/30 day mortality, the need for emergency surgery, three-year mortality or subsequent revascularization Summary: However, P-PCI centers had higher repeat TV PCI rates and higher mortality rates for patients not undergoing PCI. Conclusion: P-PCI centers should be monitored closely, including the monitoring of STEMI patients who do not undergo PCI.